2026³â09¿ù01ÀÏtue
·Î±×ÀÎ | ȸ¿ø°¡ÀÔ
OFF
Æ®À§ÅÍ·Î º¸³»±â ½ÎÀÌ¿ùµå °ø°¨
±â»ç±ÛÈ®´ë ±â»ç±ÛÃà¼Ò ±â»ç½ºÅ©·¦ À̸ÞÀϹ®ÀÇ ÇÁ¸°Æ®Çϱâ
°¡Å縯·ù¸¶Æ¼½ºæÚ, 25ÀÏ 1Â÷ ±¹Á¦Çмú´ëȸ
[ 2003³â 09¿ù 19ÀÏ 01½Ã 51ºÐ ]
°¡Å縯Áß¾ÓÀÇ·á¿ø °¡Å縯·ù¸¶Æ¼½º¿¬±¸¼¾ÅÍ(¼ÒÀå ±èÈ£¿¬ ±³¼ö)°¡ ¿À´Â 25ÀÏ Ã¹ ±¹Á¦Çмú´ëȸ¸¦ °³ÃÖÇÑ´Ù.

1ºÎ¿Í 2ºÎ, µÎ°¡Áö ÇüÅÂÀÇ ½ÉÆ÷Áö¾öÀ¸·Î ÁøÇàµÇ¸ç ¼º¸¶¸®¾Æ³ª ´ëÇаú ±³Åä ´ëÇÐ µîÀÇ Àú¸í ±³¼öµéÀÌ ¿¬ÀÚ·Î Âü°¡, Àü ¼¼°èÀûÀÎ ·ù¸¶Æ¼½º Ãß¼¼¿Í ÃÖ½ÅÁö°ßÀ» ¼Ò°³ÇÏ´Â ÀÚ¸®°¡ µÉ ¿¹Á¤ÀÌ´Ù.

¼¼ºÎ ¿¬Á¦·Î´Â ¡ãCD4+CD25+ regulatory T cells are not essential for induction and maintenance of tolerance to exogenous antigen (¼­¿ï´ë °­Ã¢À² ±³¼ö)¡ãInduction of Tolerogenic Dendritic cells expressing antigen specific CD11b+CD8 phenotype in Type II collagen Induced arthritis(°¡Å縯´ë ±èÈ£¿¬ ±³¼ö)¡ãMolecular studies DCs using microarray analysis of DC cDNA library (Çѳ²´ë ¹è¿ë¼ö ±³¼ö)¡ãAbsence of CD1d-restricted T cell selection in mice expressing CD1d with MHC class II promoter( °í·Á´ë ¹Ú¼¼È£ ±³¼ö) µîÀÌ ¹ßÇ¥µÈ´Ù.

À̾î 2ºÎ¿¡¼­´Â ¡ãThe role of altered peptide derived from collagen ¥± on T cell actiation and collagen induced arthritis - Zhanguo Li (Peking University Medical School) ¡ãGene Therapy of Rheumatoid Arthritis - Hitoshi Kohsaka (Tokyo Medical and Dental University)¡ãNovel paradigm of research and development on ¡°common¡±- rheumatic disease Osteoarthritis and Fibromyalg - Kusuki Nishioka (St.Marianna University School of Medicine) µîÀÇ ¿¬Á¦ ¹ßÇ¥°¡ ÁøÇàµÈ´Ù.

½ÉÆ÷Áö¾ö ÀÌÈÄ¿¡´Â °£´ÜÇÑ ¸®¼Á¼ÇÀÌ ¸¶·ÃµÉ ¿¹Á¤ÀÌ¸ç ¹®ÀÇ´Â °¡Å縯·ù¸¶Æ¼½º¿¬±¸¼¾ÅÍ (¢Ï02)590-2397)·Î ÇÏ¸é µÈ´Ù.
±èÇöÁ¤±âÀÚ hjkim@dailymedi.com
À̱âÀÚÀÇ ´Ù¸¥´º½ºº¸±â
¹«ÅëÀåÀÔ±Ý Á¤º¸ÀÔ·Â ÀÔ±ÝÀÚ¸í ÀԱݿ¹Á¤ÀÏÀÚ
(ÀÔ±ÝÇÏ½Ç ÀÔ±ÝÀÚ¸í + ÀԱݿ¹Á¤ÀÏÀÚ¸¦ ÀÔ·ÂÇϼ¼¿ä)
[°ü·Ã´º½º]
- °ü·Ã´º½º°¡ ¾ø½À´Ï´Ù.
Æ®À§ÅÍ·Î º¸³»±â ½ÎÀÌ¿ùµå °ø°¨
±â»ç±ÛÈ®´ë ±â»ç±ÛÃà¼Ò ±â»ç½ºÅ©·¦ À̸ÞÀϹ®ÀÇ ÇÁ¸°Æ®Çϱâ
¸íÁöº´¿ø, ͺ À̰ÇÈñ ȸÀå ÁÖÄ¡ÀÇ À̰­¿ì ±³¼ö(»ï¼º¼­¿ïº´¿ø ÀçȰÀÇÇаú) ¿µÀÔ
´ëÀü¼º¸ðº´¿ø ±èµ¿±â¡¤À̵¿Ã¢ ±³¼ö, ´ëÇÑÀ̺ñÀÎÈİúÇÐȸ ÃÖ¿ì¼ö ±¸¿¬»ó¡¤ÃÖ¿ì¼ö Æ÷½ºÅÍ»ó
Á¶Àç¿ì ±³¼ö(°í´ë±¸·Îº´¿ø Á¤Çü¿Ü°ú), ´ëÇѰñÀýÇÐȸ ÃÖ´Ù³í¹®»ó
´ëÇÑÀÇ»çÇùȸ ºÎȸÀå ¹éÇö¿í¡¤Àǹ«ÀÌ»ç ¿Àµ¿È£¡¤Á¤º¸Åë½ÅÀÌ»ç À¯¼Ò¿µèâ
Çѱ¹Á¦¾à¹ÙÀÌ¿ÀÇùȸ ÀǾàǰ±¤°í½ÉÀÇÀ§¿øÈ¸ À§¿øÀå ±è¼ºÁø¡¤ºÎÀ§¿øÀå ÀÌÁØÈñ¡¤ÀåÃá°ï èâ
¹è±â¼ö ±³¼ö(¾ÆÁִ뺴¿ø ¼Ò¾ÆÃ»¼Ò³â°ú), Á¦100ȸ ¾î¸°À̳¯ ¿ÁÁ¶±ÙÁ¤ÈÆÀå
À̺´ÈÆ¡¤½ÉÀç¾Ó ±³¼öÆÀ(±æº´¿ø Á¤Çü¿Ü°ú), ´ëÇѰñÀýÇÐȸ ¿ÃÇØ ¿ì¼ö ±¸¿¬»ó
³²°¡Àº ±³¼ö(°í´ë±¸·Îº´¿ø °¡Á¤ÀÇÇаú), Çѱ¹¿©ÀÚÀÇ»çȸ Á¦4ȸ ÀþÀºÀÇÇÐÀÚ Çмú»ó
±¹¸³Áß¾ÓÀÇ·á¿ø Áß¾ÓÀÀ±ÞÀÇ·á¼¾ÅÍÀå ±è¼ºÁß(Á¶¼±´ëº´¿ø ÀÀ±ÞÀÇÇаú ±³¼ö)
ÃÖÁ¤¿õ ¿µ°æÀÇ·áÀç´Ü ÀüÁÖº´¿ø ÀÌ»çÀå, ¾Æµ¿º¸È£»ç¾÷ ±â±Ý 4000¸¸¿ø
±è¿µÁÖ ±³¼ö(ÀÌ´ë¸ñµ¿º´¿ø »êºÎÀΰú), Á¦13ȸ Çѵ¶¿©ÀÇ»çÇмú´ë»ó
¹ÚÂùÈì ±³¼ö(ÇѸ²´ëÃáõ¼º½Éº´¿ø À̺ñÀÎÈİú), ´ëÇÑÀ̺ñÀÎÈİúÇÐȸ Çмú»ó
Á¶¼öÁø ±³¼ö(ÇѸ²´ëµ¿Åº¼º½Éº´¿ø ½Å°æ°ú), Á¦26ȸ JWÁß¿ÜÇмú´ë»ó
¼­Á¤°Ç ¿¬¼¼¼­³»°ú ¿øÀå ÀåÀλó